stent-liberador-drogas-sirolimus-everolimus

LV: Everolimus Eluting Stents vs. Coronary Artery Bypass Graft

Original Title: Revascularization in Patients with Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction: Everolimus Eluting Stents vs Coronary Artery Bypass Graft Surgery Reference: Bangalore et al. Circulation. 2016 May 5. Epub ahead of print.   Courtesy of Dr. Guillermo Migliaro.   Guidelines recommend coronary artery bypass graft surgery (CABG) over percutaneous coronary<a href="https://solaci.org/en/2016/05/16/lv-everolimus-eluting-stents-vs-coronary-artery-bypass-graft/" title="Read more" >...</a>

Aspirin or Clopidogrel as Monotherapy after 12 month DAPT

Original Title: Clopidogrel versus Aspirin as an Antiplatelet Monotherapy after 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents. Reference: Taek Kyu Park et al. Circ Cardiovasc Interv. 2016 Jan;9(1):e002816. Courtesy of Dr. José Amadeo Guillermo Álvarez. The use of dual antiplatelet therapy (DAPT) over 12 months after hospitalization for acute myocardial infarction (AMI) or drug<a href="https://solaci.org/en/2016/02/04/aspirin-or-clopidogrel-as-monotherapy-after-12-month-dapt/" title="Read more" >...</a>

Triple Antithrombotic Scheme in AMI Patients undergoing PCI

Original Title: Outcomes of Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy, a Comparison of Clopidogrel vs. Prasugrel from the TRANSLATE-ACS Study. Reference: Jackson L.R. et al. JACC Cardiovasc Interv. 2015 Dec 21;8(14):1880-9. Courtesy of Dr Agustín Vecchia. In these last years, new and more powerful antiaggregants have<a href="https://solaci.org/en/2016/01/29/triple-antithrombotic-scheme-in-ami-patients-undergoing-pci/" title="Read more" >...</a>

Meta-Analysis of Bioresorbable Vascular Scaffolds vs. Everolimus Eluting Stents

 Courtesy of Dr. Agustín Vecchia. The aim of this study was to compare the safety and efficacy of bioresorbable everolimus eluting scaffolds (BVS) vs. everolimus eluting stents (EES) in patients with ischemic heart disease.   Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), was searched for scientific sessions, abstracts, and relevant websites for<a href="https://solaci.org/en/2016/01/19/meta-analysis-of-bioresorbable-vascular-scaffolds-vs-everolimus-eluting-stents/" title="Read more" >...</a>

Dual Antiplatelet Therapy after Everolimus Eluting Stenting

Original Title: Benefits and Risks of Extended Dual Antiplatelet Therapy after Everolimus-Eluting Stents. For the Dual Antiplatelet Therapy (DAPT) Study Investigators. Reference: James B. Hermiller et al. JACC: Cardiovascular Interventions 2015, online before print. The DAPT study had shown that continued aspirin plus thienopyridine beyond a year reduces ischemic events. Given the fairly low rate of thrombosis<a href="https://solaci.org/en/2015/12/11/dual-antiplatelet-therapy-after-everolimus-eluting-stenting/" title="Read more" >...</a>

ABSORB III: Everolimus Eluting Bioresorbable Scaffolds for Coronary Artery Disease

Original Title: Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. Reference: Stone, M.D. for the ABSORB III Investigators. N Engl J Med 2015;373:1905-1915. The ABSORB III is part of a series of randomized studies that test bioresorbable scaffolds in the clinical practice (ABSORB II, EVERBIO II, ABSORB Japan, and ABSORB IV). 2008 patients were randomized; 60% had<a href="https://solaci.org/en/2015/11/20/absorb-iii-everolimus-eluting-bioresorbable-scaffolds-for-coronary-artery-disease/" title="Read more" >...</a>

Polymer Free Drug Coated Stent in High Bleeding Risk Patients with Only One Month DAPT

Original Title: Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk Reference: Philip Urban et al. N Engl J Med. 2015 Oct 14. [Epub ahead of print]. High bleeding risk patients undergoing PCI usually receive conventional bare metal stents (BMS) to allow the shortest possible DAPT (dual antiplatelet therapy), usually a month long. This<a href="https://solaci.org/en/2015/11/16/polymer-free-drug-coated-stent-in-high-bleeding-risk-patients-with-only-one-month-dapt/" title="Read more" >...</a>

TOTAL stroke: increased risk of stroke with thromboaspiration

There are many doubts about the benefit of manual thromboaspiration, not only in terms of improvement of the clinical end point but also the potential risk of stroke. The TOTAL (n = 10732) was a randomized study of routine manual thrombectomy versus angioplasty only in the context of ST segment elevation acute myocardial infarction and<a href="https://solaci.org/en/2015/06/24/total-stroke-increased-risk-of-stroke-with-thromboaspiration/" title="Read more" >...</a>

TOTAL OCT: Thrombotic load of culprit lesion using OCT. TOTAL substudy.

The thrombotic load of culprit lesion is unidentified in the context of acute myocardial infarction that vindicates the use of thromboaspiration. This work is a substudy of TOTAL in patients underwent OCT before stenting. 214 patients randomized to thromboaspiration or only angioplasty were included. No differences between groups in plaque load, thrombus absolute volume, or<a href="https://solaci.org/en/2015/06/24/total-oct-thrombotic-load-of-culprit-lesion-using-oct-total-substudy/" title="Read more" >...</a>

BEST: Similar mortality among angioplasty with DES (everolimus) and surgery

This observational registry compared the results of myocardial revascularization with angioplasty performed using everolimus-eluting stents in patients with multivessel. The primary endpoint of the study was mortality from any cause. Side end points were infarction, stroke, and revascularization. Propensity score was used to compare populations. Between 34819 patients were eligible 9223 patients in each group<a href="https://solaci.org/en/2015/06/24/best-similar-mortality-among-angioplasty-with-des-everolimus-and-surgery/" title="Read more" >...</a>